By David Wild
Originally published by our sister publication, Gastroenterology & Endoscopy News
Some Crohn’s disease patients may require 24 weeks before experiencing a response to treatment with risankizumab. More than 60% of patients with Crohn’s disease who did not respond adequately to 12 weeks of IV risankizumab had a clinical response when given an additional 12 weeks of the drug, according to a study presented at United European Gastroenterology Week 2021 (abstract